Dossier assessment
Vandetanib (medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the limitation period)
Report documents
-
Extract of dossier assessment
Vandetanib (medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the limitation period)
-
Dossier assessment
Vandetanib (medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the limitation period)
Dossier assessment
Treatment of aggressive and symptomatic medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease
Added benefit not proven.
Project details
- Project no.
- A21-127
- Commission
- Commission awarded on 01.10.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Vandetanib (medullary thyroid carcinoma in children and adolescents from the age of 5) – Benefit assessment according to § 35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Vandetanib (second assessment) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Vandetanib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed